Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0001577 (
adnexitis
)
232
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Ceftazidime (
CAZ
) was evaluated for its clinical efficacy in a total of 12 cases, namely 3 cases of endometritis, 3 cases of intrapelvic infections, 4 cases of
adnexitis
and 2 cases of external genital infections. In all the cases,
CAZ
was administered by intravenous drip infusion, and the duration of the treatment ranged from 3 to 22 days. Daily dose was 2 g in 10 cases, and in the remaining 2 cases, daily doses were changed during the course of treatment in the range from 2 to 4 g. The clinical results of
CAZ
by disease were as follows; excellent in 1 case and good in 2 cases of endometritis, good in all the 3 cases of intrapelvic infections and the 4 cases of
adnexitis
, and excellent in 1 case and good in 1 case of external genital infections. The overall efficacy rate was 100%, namely, excellent in 2 cases and good in 10 cases of the total of 12 cases. Neither side effects nor abnormal laboratory findings attributable to
CAZ
were observed in any of the case. From these results, we may conclude that
CAZ
is a safe antibiotic with satisfactory clinical effects on gynecological infections.
...
PMID:[Clinical efficacy of ceftazidime in inflammatory diseases in the field of gynecology]. 637 90
Ceftazidime (
CAZ
) exhibited in vitro activity greater than cefoperazone, cefotiam, cefmetazole and cefazolin and almost equal to cefotaxime (CTX), ceftizoxime (CZX) and latamoxef ( LMOX ) against E. coli and K. pneumoniae isolated from obstetrical or gynecological infections excluding urinary tract infections. This drug demonstrated less activity than other 6 cephems against B. fragilis. Against anaerobic Gram-positive cocci, it showed less activity than other cephems.
CAZ
was administered to 11 patients with obstetrical and gynecological infections. The clinical results of this drug were as follows; excellent in each 1 case of parametritis , wound infection and BARTHOLIN's abscess, good in 7 cases including 1 of puerperal fever, 2 of intrauterine infection and 4 of
adnexitis
, and poor in 1 cases of
adnexitis
. No side effects or haematobiochemical abnormalities were observed throughout this trial.
...
PMID:[Ceftazidime: antibacterial activity and clinical efficacy in obstetrics and gynecology]. 637 92
Ceftazidime (
CAZ
), a new cephalosporin antibiotic, was fundamentally and clinically studied. The following results were obtained. Serum and internal genital tissue levels of
CAZ
were measured following intravenous drip infusion of 1 g for 30 minutes. Serum levels of more than 10 micrograms/ml and tissue levels of more than about 7 micrograms/ml were maintained after 2 hours to 2 hours and 30 minutes, respectively. Favourable transfer of
CAZ
into the pelvic dead space exudate was observed. The exudate level attained its peak of 31.54 micrograms/ml on average at 2 hours and was 16.8 micrograms/ml on average even at 8 hours after intravenous drip infusion. A total of 6 cases comprising 1 of
adnexitis
, 2 of pyometra, 1 of endometritis and 2 of parametritis was treated with
CAZ
at a dose of 0.5 approximately 2.0 g twice daily by intravenous injection or intravenous drip infusion. The clinical response was excellent in 1 case, good in 4 cases and poor in 1 case. Abnormal laboratory findings and side effects due to the drug were not noted.
...
PMID:[Fundamental and clinical studies of ceftazidime in the field of obstetrics and gynecology]. 637 96
Ceftazidime (
CAZ
) was studied for the transfer into intrapelvic tissues and for the clinical efficacy in the treatment of 20 cases of obstetrical and gynecological infections. Transfer into the tissues--Following intravenous 1 hour-drip infusion of 1 g, favourable transfer of
CAZ
into intrapelvic tissues was observed. The peak drug level of 50 approximately 66 micrograms/g was obtained at 5 approximately 36 minutes after completion of the administration. Clinical evaluation--
CAZ
was administered at a daily dose of 2 approximately 4 g in 1 approximately 4 divided doses by intravenous drip infusion for 90 minutes. The subjects were patients with the following infections; pyometra (1), puerperal endometritis (3), parametritis (5), pelvioperitonitis (3), purulent lymphocytes (2), retroperitoneal abscess (1) and acute
adnexitis
(5). Clinical efficacy was; excellent in 15 cases, good in 3 cases and poor in 2 cases, with the overall efficacy rate of 90.0%. No notable side effects or abnormal laboratory findings were observed except for eruption in 1 case.
...
PMID:[Fundamental and clinical studies on ceftazidime in the field of obstetrics and gynecology]. 637 99
Basic and clinical studies on ceftazidime (
CAZ
) were carried out in the field of obstetrics and gynecology. The following results were obtained. The
CAZ
levels in the pelvic dead space exudate and serum were measured with passage of time in patients undergoing radical hysterectomy with pelvic lymphadenectomy for uterine cervical cancer after intravenous drip infusion of 1 g for 30 minutes. The serum level attained the peak of 87.0 micrograms/ml immediately after completion of the drip infusion and rapidly decreased thereafter. On the other hand, the pelvic dead space exudate level reached the peak of 27.9 micrograms/ml at 1 hour after completion of the drip infusion and gradually decreased thereafter, keeping higher levels than the serum levels. A total of 10 cases comprising 2 of
adnexitis
, 1 of pelvioperitonitis , 2 of pyometra and 5 of BARTHOLIN's abscess was treated with
CAZ
intravenous injection at a dose of 1 g twice daily for 5 approximately 6 days. The clinical efficacy was excellent in 1 case and good in 9 cases. Neither adverse reactions nor abnormal laboratory findings were observed in any of the cases.
...
PMID:[Basic and clinical studies on ceftazidime in the field of obstetrics and gynecology]. 637